Spots Global Cancer Trial Database for hematologic and lymphocytic disorder
Every month we try and update this database with for hematologic and lymphocytic disorder cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | NCT04339101 | Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo... | Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers | NCT03207854 | Healthy Subject Hematologic and... Hematopoietic a... Immune System D... Malignant Neopl... | Biospecimen Col... Laboratory Biom... Questionnaire A... | 19 Years - | University of Southern California | |
| Parenting Skills Intervention in Improving Medication Adherence in Pediatric Cancer Patients | NCT03895918 | Guardian Hematologic and... Malignant Neopl... Parent | Educational Act... Patient Monitor... Questionnaire A... | 18 Years - | Roswell Park Cancer Institute | |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | NCT03195010 | Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... B-Cell Non-Hodg... Chronic Lymphoc... Chronic Myeloge... Hematologic and... Hematopoietic C... Myelodysplastic... Primary Myelofi... Secondary Myelo... T-Cell Non-Hodg... Thrombocytopeni... Venous Thromboe... | Platelet Transf... Platelet Transf... | 18 Years - | Fred Hutchinson Cancer Center | |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | NCT04339101 | Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo... | Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | NCT04339101 | Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo... | Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| Parenting Skills Intervention in Improving Medication Adherence in Pediatric Cancer Patients | NCT03895918 | Guardian Hematologic and... Malignant Neopl... Parent | Educational Act... Patient Monitor... Questionnaire A... | 18 Years - | Roswell Park Cancer Institute | |
| Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation | NCT04127721 | Allogeneic Stem... Hematologic and... Hematopoietic a... | Allogeneic Hema... Busulfan Fludarabine Itacitinib Methotrexate Tacrolimus | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | NCT04062266 | Acute Myeloid L... FLT3 Gene Mutat... Hematologic and... Acute Myeloid L... Minimal Residua... Therapy-Related... | Azacitidine Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant | NCT04572815 | Hematologic and... Hematopoietic a... | Placebo Adminis... Quality-of-Life... Questionnaire A... Ustekinumab | 18 Years - 70 Years | Fred Hutchinson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
